BioMarin Withdraws European Application for Kyndrisa - Genetic Engineering & Biotechnology News

BioMarin Withdraws European Application for Kyndrisa Genetic Engineering & Biotechnology News BioMarin Pharmaceutical said today it has withdrawn its Marketing Authorization Application (MAA) for Kyndrisa™ (drisapersen), the company's drug candidate for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. BioMarin said it will also ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGmrV6dTzgxyu22M_4OQy7ryn_bcg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779124020706&ei=qPJOV4iLM9SS3QH7i4GwBg&url=http://www.genengnews.com/gen-news-highlights/biomarin-withdraws-european-application-for-kyndrisa/81252778/
via IFTTT